<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-id journal-id-type="publisher-id">wox</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization Journal</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3512925</article-id><article-id pub-id-type="doi">10.1097/01.WOX.0000411944.28600.9b</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts of the XXII World Allergy Congress</subject></subj-group><subj-group subj-group-type="heading"><subject>Poster Symposium</subject></subj-group><series-title>Asthma Treatment</series-title></article-categories><title-group><article-title>187&#x02003;Reduction in Asthma Deteriorations in Subjects with Persistent Asthma not Well Controlled on Low-, Medium-, or High-Dose Inhaled Corticosteroids: A Pooled Analysis From Three Clinical Trials Using Combined Mometasone Furoate/Formoterol</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Weinstein</surname><given-names>Steven</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nathan</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Meltzer</surname><given-names>Eli</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gates</surname><given-names>Davis</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Nolte</surname><given-names>Hendrik</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Allergy &#x00026; Asthma Specialists Medical Group, Huntington Beach, CA</aff><aff id="aff2"><label>2</label>Asthma &#x00026; Allergy Associates, P.C. and Research Center, Colorado Springs, CO</aff><aff id="aff3"><label>3</label>Allergy and Asthma Medical Group &#x00026; Research Center, San Diego, CA</aff><aff id="aff4"><label>4</label>Schering-Plough Research Institute (now Merck Research Laboratories), Kenilworth, NJ</aff><aff id="aff5"><label>5</label>Merck Research Laboratories, Kenilworth, NJ.</aff><pub-date pub-type="epub"><day>17</day><month>2</month><year>2012</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2012</year></pub-date><volume>5</volume><issue>Suppl 2</issue><issue-title>Abstracts of the XXII World Allergy Congress, 4&#x02013;8 December, 2012 Canc&#x000fa;n, M&#x000e9;xico</issue-title><fpage seq="a">S79</fpage><lpage>S79</lpage><permissions><copyright-statement>Copyright &#x000a9; 2012 by World Allergy Organization</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="waoj-5-S79.pdf"/><abstract><sec><title>Background</title><p>We present a post hoc analysis from 3 phase III clinical trials examining the effects of mometasone furoate/formoterol (MF/F) combination therapy on asthma deterioration in subjects previously not well controlled on low-, medium-, or high-dose inhaled corticosteroids (ICS).</p></sec><sec><title>Methods</title><p>A 2- to 3-week run-in period with twice-daily (BID) MF 100 &#x003bc;g (MF/F 100/10 &#x003bc;g BID study), MF 200 &#x003bc;g (MF/F 200/10 &#x003bc;g BID study), or MF 400 &#x003bc;g (MF/F 400/10 &#x003bc;g BID study) was performed before subjects (aged &#x02265;12 years) were randomized to BID: MF/F 100/10 &#x003bc;g, MF 100 &#x003bc;g, F 10 &#x003bc;g, or placebo for 26 weeks (n = 746; MF/F 100/10 &#x003bc;g BID study); MF/F 200/10 &#x003bc;g, MF 200 &#x003bc;g, F 10 &#x003bc;g, or placebo for 26 weeks (n = 781; MF/F 200/10 &#x003bc;g BID study); or MF/F 200/10 &#x003bc;g, MF/F 400/10 &#x003bc;g, or MF 400 &#x003bc;g for 12 weeks (n = 728; MF/F 400/10 &#x003bc;g BID study). Assessment of asthma deterioration (ie, 20% decrease in forced expiratory volume in 1 s [FEV<sub>1</sub>], 30% decrease in peak expiratory flow [PEF] on &#x02265;2 consecutive days, or clinically judged deterioration [ie, emergency treatment, hospitalization, or treatment with excluded medications]) was a coprimary endpoint for the MF/F 100/10 &#x003bc;g BID and 200/10 &#x003bc;g BID studies and a secondary endpoint for the MF/F 400/10 &#x003bc;g BID study. Post hoc pair-wise comparisons of pooled MF/F vs pooled MF, F, and placebo treatment groups were performed.</p></sec><sec><title>Results</title><p>Sample sizes in this pooled analysis were 861 for MF/F, 620 for MF, 390 for F, and 384 for placebo. There was a significantly lower incidence of asthma deterioration with MF/F (17.2%) versus MF (26.1%; <italic>P</italic> = 0.002), F (49.5%; <italic>P</italic> &#x0003c; 0.001), and placebo (50.8%; <italic>P</italic> &#x0003c; 0.001). Incidence of individual asthma deterioration criteria was 7.0% for MF/F, 10.0% for MF, 13.8% for F, and 17.7% for placebo for FEV<sub>1</sub> reduction; 7.5%, 12.6%, 27.2%, and 26.3%, respectively, for PEF reduction; and 2.1%, 2.6%, 6.7%, and 5.2% for clinically judged deterioration.</p></sec><sec><title>Conclusions</title><p>MF/F-treated subjects experienced a significantly lower rate of asthma deterioration compared with MF, F, and placebo in subjects previously not well controlled on low-, medium-, or high-dose ICS.</p></sec></abstract></article-meta></front></article>